Brilinta granted FDA Priority Review for the reduction of subsequent stroke in patients who had an acute ischemic stroke or transient ischemic attack

Click here to view online. Add this email to your safelist.

9 July 2020

AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Brilinta (ticagrelor) for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack (TIA).

RSS Feed

Legal notice and Terms of Use

Cookie policy

Site map

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.